Call for Abstracts and Travel Awards: All authors notified by email  ︎  18 invited speakers confirmed  ︎  Save your seat! Register here until October 7  ︎  Check the programme at a glance  ︎  Interested in joining the team of volunteers? Apply now!   ︎  Become a partner of #CRSy22  ︎ 
︎    ︎    ︎    

Michelle Monje, MD, PhD



Professor of Neurology @Stanford University
Investigator @Howard Hughes Medical Institute


Stanford, United States of America


Michelle Monje, MD, PhD, is a Professor of Neurology and Neurological Sciences at Stanford University and a Howard Hughes Medical Institute Investigator. She received her M.D. and Ph.D. in Neuroscience from Stanford and completed her residency training in neurology at the Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical School Partners program, and then returned to Stanford for a clinical fellowship in pediatric neuro-oncology and postdoctoral fellowship in developmental and cancer biology.

Dr. Monje is recognized as an international leader in the pathophysiology of glioma, especially diffuse intrinsic pontine glioma (DIPG)/H3K27M-mutated diffuse midline gliomas and a pioneer in the emerging field of Cancer Neuroscience.

Her clinical focus is on childhood glial malignancies and cognitive impairment after childhood cancer therapy. Her laboratory studies neuron-glial interactions in health and disease, with a particular focus on mechanisms and consequences of neuron-glial interactions in health, glial dysfunction in cancer therapy-related cognitive impairment and neuron-glial interactions in malignant glioma.

Together with these basic studies, her research program has advanced preclinical studies of novel therapeutics for pediatric high-grade gliomas and cancer therapy-related cognitive impairment in order to translate new therapies to the clinic. She has led several of her discoveries from basic molecular work to clinical trials for children and young adults with brain tumors.

Visit the speaker’s lab here︎

This symposium is supported by QuantOCancer Project funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement Nº 810653.